Ana M. Aparicio
A5021183845- Prostate Cancer Treatment and Research
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Microtubule and mitosis dynamics
- Neuroblastoma Research and Treatments
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Hormonal and reproductive studies
- Colorectal Cancer Treatments and Studies
- Renal cell carcinoma treatment
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
The University of Texas MD Anderson Cancer Center
2016-2025
Mayo Clinic Hospital
2024
Anderson University - South Carolina
2024
University of California, San Diego
2024
University of Southern California
2001-2023
Texas Oncology
2022
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2021
Hospital Universitario Reina Sofía
2021
Scripps MD Anderson Cancer Center
2021
Stanford University
1997-2018
Abstract Purpose: Clinical features characteristic of small-cell prostate carcinoma (SCPC), “anaplastic,” often emerge during the progression cancer. We sought to determine efficacy platinum-based chemotherapy in patients meeting at least one seven prospectively defined “anaplastic” clinical criteria, including exclusive visceral or predominantly lytic bone metastases, bulky tumor masses, low prostate-specific antigen levels relative burden, short response androgen deprivation therapy....
Cancers with loss-of-function mutations in BRCA1 or BRCA2 are deficient the DNA damage repair pathway called homologous recombination (HR), rendering these cancers exquisitely vulnerable to poly(ADP-ribose) polymerase (PARP) inhibitors. This functional state and therapeutic sensitivity is referred as "BRCAness" most commonly associated some breast cancer types. Pharmaceutical induction of BRCAness could expand use PARP inhibitors other tumor For example, BRCA present only ~20% prostate...
Yeasty HIPHOP In order to identify how chemical compounds target genes and affect the physiology of cell, tests perturbations that occur when treated with a range pharmacological chemicals are required. By examining haploinsufficiency profiling (HIP) homozygous (HOP) chemogenomic platforms, Lee et al. (p. 208 ) analyzed response yeast thousands different small molecules, genetic, proteomic, bioinformatic analyses. Over 300 were identified targeted 121 within 45 cellular signature networks....
Abstract Purpose: Morphologically heterogeneous prostate cancers that behave clinically like small-cell (SCPC) share their chemotherapy responsiveness. We asked whether these defined, morphologically diverse, “aggressive variant cancer (AVPC)” also molecular features with SCPC. Experimental Design: Fifty-nine samples from 40 clinical trial participants meeting AVPC criteria, and 8 patient-tumor derived xenografts (PDX) 6 of them, were stained for markers aberrantly expressed in DNA 36 PDX...
Enhancer of zeste homolog 2–mediated (EZH2-mediated) epigenetic regulation T cell differentiation and Treg function has been described previously; however, the role EZH2 in cell–mediated antitumor immunity, especially context immune checkpoint therapy, is not understood. Here, we showed that genetic depletion Tregs (FoxP3creEZH2fl/fl mice) leads to robust immunity. In addition, pharmacological inhibition human cells using CPI-1205 elicited phenotypic functional alterations enhanced cytotoxic...
Significance Immune checkpoint therapies have garnered significant attention due to their ability induce dramatic clinical responses in patients with various solid tumor malignancies, including prostate cancer. However, these therapeutic agents often elicit immune-related adverse events (irAEs) that may result substantial morbidity. Early intervention can markedly reduce the severity of irAEs, but biomarkers allow for early detection and guide management are lacking. Based on peripheral...
Despite evidence demonstrating an overall survival benefit with up-front hormone therapy in addition to established synergy between and radiation, the of metastasis-directed (MDT) for oligometastatic prostate cancer, date, has not been evaluated a randomized clinical trial.
Innovations in imaging and molecular characterisation the evolution of new therapies have improved outcomes advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas management.To present consensus voting results for select questions from APCCC 2022.Before conference,...
Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts key questions clinical management order supplement evidence-based guidelines. Here present voting results for from APCCC 2024.
Abstract Purpose: The primary goal of this trial was to determine the response rate single-agent vorinostat in patients with metastatic breast cancer. secondary goals included assessment time progression, evaluation toxicities, and overall survival. Experimental Design: From June 2005 March 2006, 14 received vorinostat, 200 mg p.o., twice daily for days each 21 day cycle. Response progression were evaluated using Evaluation Criteria Solid Tumors (RECIST) criteria. Results: median age all...
Purpose To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), to explore the hypothesis that pretreatment antiangiogenic therapy will select who benefit most from cytoreductive nephrectomy. Patients Methods newly diagnosed, clear mRCC whose primary tumors were considered resectable enrolled. In this single-arm, phase II trial, received plus erlotinib (first patients, n = 23) or alone (n 27 patients) for 8 weeks followed by...
Abstract Purpose: Small-cell prostate carcinoma (SCPC) morphology predicts for a distinct clinical behavior, resistance to androgen ablation, and frequent but short responses chemotherapy. We sought develop model systems that reflect human SCPC can improve our understanding of its biology. Experimental Design: developed set castration-resistant carcinomas xenografts examined their fidelity tumors origin. compared the expression genomic profiles large-cell neuroendocrine (LCNEC) those typical...
Low–tumor mutational burden prostate tumors express neoantigens that elicit T cell responses associated with favorable clinical outcomes to ipilimumab.